help button home button Am J Pathol ASIP MEMBERSHIP
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nie, K.
Right arrow Articles by Tam, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nie, K.
Right arrow Articles by Tam, W.
(American Journal of Pathology. 2008;173:242-252.)
© 2008 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2008.080009

MicroRNA-Mediated Down-Regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg Cells: A Potential Pathogenetic Lesion in Hodgkin Lymphomas

Kui Nie*, Mario Gomez*, Pablo Landgraf{dagger}, Jose-Francisco Garcia{ddagger}, Yifang Liu*, Leonard H.C. Tan§, Amy Chadburn*, Thomas Tuschl{dagger}, Daniel M. Knowles* and Wayne Tam*

From the Department of Pathology and Laboratory Medicine,* Joan and Sanford I. Weill Medical College of Cornell University, New York, New York; the Howard Hughes Medical Institute, Laboratory of RNA Molecular Biology,{dagger} The Rockefeller University, New York, New York; the Monoclonal Antibodies Unit,{ddagger} Biotechnology Program, Spanish National Cancer Center, Madrid, Spain; and the Department of Pathology,§ Singapore General Hospital, Singapore

PRDM1/Blimp-1, a master regulator in terminal B-cell differentiation, has been recently identified as a tumor suppressor target for mutational inactivation in diffuse large B-cell lymphomas of the activated B-cell type. Our studies here demonstrate that PRDM1/blimp-1 is also a target for microRNA (miRNA)-mediated down-regulation by miR-9 and let-7a in Hodgkin/Reed-Sternberg (HRS) cells of Hodgkin lymphoma (HL). MiRNA expression profiling by direct miRNA cloning demonstrated that both of these miRNAs are among the most highly expressed in cultured HRS cells. These miRNAs functionally targeted specific binding sites in the 3' untranslated region of PRDM1/blimp-1 mRNA and repressed luciferase reporter activities through repression of translation. In addition, high levels of miR-9 and let-7a in HL cell lines correlated with low levels of PRDM1/Blimp-1. Similar to their in vitro counterparts, the majority of HRS cells in primary HL cases showed weak or no PRDM1/Blimp-1 expression. Over-expression of miR-9 or let-7a reduced PRDM1/Blimp-1 levels in U266 cells by 30% to 50%, whereas simultaneous inhibition of their activities in L428 cells resulted in an approximately 2.6-fold induction in PRDM1/Blimp-1. MiRNA-mediated down-regulation of PRDM1/Blimp-1 may contribute to the phenotype maintenance and pathogenesis of HRS cells by interfering with normal B-cell terminal differentiation, thus representing a novel molecular lesion, as well as a potential therapeutic target in HL.




This article has been cited by other articles:


Home page
 BloodHome page
R. Malumbres, K. A. Sarosiek, E. Cubedo, J. W. Ruiz, X. Jiang, R. D. Gascoyne, R. Tibshirani, and I. S. Lossos
Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas
Blood, April 16, 2009; 113(16): 3754 - 3764.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
F. Bazzoni, M. Rossato, M. Fabbri, D. Gaudiosi, M. Mirolo, L. Mori, N. Tamassia, A. Mantovani, M. A. Cassatella, and M. Locati
Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals
PNAS, March 31, 2009; 106(13): 5282 - 5287.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Society for Investigative Pathology.